All Updates

All Updates

icon
Filter
Partnerships
Geographic expansion
Optimi Health to enter Asian market with PsiloThai collaboration on psilocybin research
Psychedelic Medicine
Jul 23, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Jul 23, 2024

Optimi Health to enter Asian market with PsiloThai collaboration on psilocybin research

Partnerships
Geographic expansion

  • Canada-based psychedelic drug manufacturer Optimi Health has partnered with PsiloThai, a patient advocacy group in Thailand. This collaboration follows Thailand's recent regulatory change permitting the use of psilocybin for medical treatment, research, and clinical trials. It marks Optimi's entry into the Asian medical market for observational studies involving psilocybin in patients with addiction and end-of-life distress.

  • The partnership aims to validate Optimi's GMP natural psilocybin extract capsules and explore psilocybin's therapeutic potential. It also allows Optimi to leverage PsiloThai's research capabilities and tap into Thailand's healthcare facilities and patient base.

  • Analyst QuickTake: Optimi previously expanded into the Israeli psychedelics market through a partnership with Tel Aviv University in March 2024. Additionally, its recent collaboration with Mind Medicine Australia to launch a resource platform for Australian psychiatrists underscores its commitment to supply safe psychedelic drugs globally.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.